PDS Biotechnology Files 8-K
Ticker: PDSB · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
PDS Biotech filed a routine 8-K, no major news.
AI Summary
PDS Biotechnology Corporation filed an 8-K on October 2, 2024, to report on other events and financial statements. The filing does not detail specific new events or financial figures but serves as a notification of ongoing reporting requirements.
Why It Matters
This filing indicates PDS Biotechnology is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard SEC filing for ongoing reporting and does not disclose new material information.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- October 2, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-37568 (company_id) — SEC File Number
- 26-4231384 (company_id) — I.R.S. Employer Identification No.
- 303A College Road East, Princeton, NJ 08540 (address) — Principal Executive Offices
- Edge Therapeutics, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on other events and financial statements as required by the SEC.
What is the filing date of this 8-K?
The filing date of this 8-K is October 2, 2024.
What is the company's state of incorporation?
The company, PDS Biotechnology Corporation, is incorporated in Delaware.
What was the former name of PDS Biotechnology Corporation?
The former name of PDS Biotechnology Corporation was Edge Therapeutics, Inc.
Does this filing disclose any new material events or financial results?
This filing does not appear to disclose specific new material events or detailed financial results, but rather serves as a notification of ongoing reporting.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-02 08:05:27
Key Financial Figures
- $0.00033 — h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar
Filing Documents
- ef20036539_8k.htm (8-K) — 31KB
- ef20036539_ex99-1.htm (EX-99.1) — 25KB
- ef20036539_ex99-2.htm (EX-99.2) — 19KB
- ef20036539_ex99-2slide1.jpg (GRAPHIC) — 188KB
- ef20036539_ex99-2slide2.jpg (GRAPHIC) — 94KB
- ef20036539_ex99-2slide3.jpg (GRAPHIC) — 172KB
- ef20036539_ex99-2slide4.jpg (GRAPHIC) — 155KB
- ef20036539_ex99-2slide5.jpg (GRAPHIC) — 168KB
- ef20036539_ex99-2slide6.jpg (GRAPHIC) — 199KB
- ef20036539_ex99-2slide7.jpg (GRAPHIC) — 126KB
- ef20036539_ex99-2slide8.jpg (GRAPHIC) — 130KB
- ef20036539_ex99-2slide9.jpg (GRAPHIC) — 124KB
- ef20036539_ex99-2slide10.jpg (GRAPHIC) — 121KB
- ef20036539_ex99-2slide11.jpg (GRAPHIC) — 106KB
- ef20036539_ex99-2slide12.jpg (GRAPHIC) — 183KB
- image0.jpg (GRAPHIC) — 241KB
- 0001140361-24-042537.txt ( ) — 2986KB
- pdsb-20241002.xsd (EX-101.SCH) — 4KB
- pdsb-20241002_lab.xml (EX-101.LAB) — 21KB
- pdsb-20241002_pre.xml (EX-101.PRE) — 16KB
- ef20036539_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On October 2, 2024, PDS Biotechnology Corporation (the "Company") issued a press release announcing that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2024 in an oral presentation by Adam Grippin, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center. The abstract was granted Basic/Translational Science Award from the ASTRO Annual Meeting Steering Committee. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. .
01
Item 8.01 Other Events. The information set forth in the press release referred to in Item 7.01 above, other than the second and fourth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. In addition, on October 2, 2024, the Company added the presentation from the ASTRO meeting to its corporate website. A copy of the presentation is filed herewith as Exhibit 99.2 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated October 2, 2024 99.2 ASTRO Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: October 2, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D Title: President and Chief Executive Officer